Clinical trials: Primary Open Angle Glaucoma
Glaucoma, Open-Angle, Ocular Hypertension
A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension
This study will evaluate 0.15% brimonidine tartrate in patients with primary open angle glaucoma and ocular hypertension.
- Trial name
- APOTUS (NCT02003534)
- Testing
- 0.15% Brimonidine Tartrate
- Where
- China
- Volunteers
- 376 people
- Sponsor
- Allergan
Primary Open Angle Glaucoma or Ocular Hypertension
Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension
To test the safety and effectiveness of AR-13324 0.02% and 0.04% ophthalmic solution relative to placebo in Japanese/Japanese-American subjects with open-angle glaucoma or ocular hypertension in US.
- Trial name
- NCT03310580
- Testing
- AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%
- Where
- 40 sites in United States
- Volunteers
- 42 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma, Open-Angle, Ocular Hypertension
Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
This is an observational study of Lumigan® 0.01% (bimatoprost) treatment in clinical practice for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
- Trial name
- NCT01628588
- Testing
- bimatoprost 0.01%
- Where
- Netherlands
- Volunteers
- 854 people
- Sponsor
- Allergan
Ocular Hypertension, Primary Open-Angle Glaucoma
Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
This study has 2 parts. Part 1 will evaluate the safety and IOP effects of 6 formulations of AGN-210961 ophthalmic solution in the study eye and bimatoprost ophthalmic solution 0.03% in the fellow eye for 7 consecutive days.
- Trial name
- NCT01110499
- Testing
- AGN-210961 Formulation 1, AGN-210961 Formulation 2, AGN-210961 Formulation 3
- Where
- United States
- Volunteers
- 163 people
- Sponsor
- Allergan
Primary Open Angle Glaucoma (POAG), Cataract
Study of an Implantable Device for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery
The purpose of this study is to evaluate the safety and efficacy of the CyPass Implant for lowering intraocular pressure (IOP) in patients with glaucoma who undergo cataract surgery.
- Trial name
- COMPASS (NCT01085357)
- Testing
- Cataract Surgery, CyPass Micro-Stent
- Volunteers
- 897 people
- Sponsor
- Transcend Medical, Inc.
Glaucoma
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil
The purpose of this study was to assess the efficacy and tolerability of changing to AZARGA® from prior COMBIGAN® pharmacotherapy in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01514734
- Testing
- Brinzolamide/timolol maleate fixed combination
- Where
- Brazil
- Volunteers
- 9 people
- Sponsor
- Alcon Research
Glaucoma, Primary Open Angle, Ocular Hypertension
A Study of LUMIGAN® RC in the Clinical Setting
This study will evaluate bimatoprost 0.01% (LUMIGAN® RC) in patients with elevated intraocular pressure (IOP) due to primary open angle glaucoma (POAG) or ocular hypertension (OHT) in a clinical setting.
- Trial name
- NCT01833741
- Testing
- Bimatoprost 0.01%
- Where
- Canada
- Volunteers
- 1,137 people
- Sponsor
- Allergan
Primary Open Angle Glaucoma, Ocular Hypertension
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
This study will evaluate the safety and efficacy of PF 03187207.
- Conditions
- Primary Open Angle Glaucoma, Ocular Hypertension, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma
- Trial name
- NCT00441883
- Testing
- PF-03187207 and Latanoprost Vehicle, Latanoprost 0.005% and PF-03187207 Vehicle
- Where
- 19 sites in United States
- Volunteers
- 176 people
- Sponsor
- Bausch & Lomb Incorporated
Glaucoma, Open-Angle, Ocular Hypertension
A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
An observational study comparing changing from an IOP-lowering treatment to a bimatoprost-containing IOP treatment in primary open-angle glaucoma (POAG) or ocular hypertension (OHT).
- Trial name
- NCT01646151
- Testing
- Bimatoprost
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 2,580 people
- Sponsor
- Allergan
Open-angle Glaucoma, Ocular Hypertension
A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study
Treatment of elevated pressure in the eye (Intraocular pressure, or 'IOP') with eye drop medications has been shown to be effective in delaying or preventing the progression of glaucoma, and it is the only proven method for…
- Trial name
- NCT03216902
- Testing
- Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution, Topical ultra-low dose of DE-126 Ophthalmic Solution, Topical low dose of DE-126 Ophthalmic Solution
- Where
- 17 sites in United States, Japan
- Volunteers
- 241 people
- Sponsor
- Santen Inc.
Primary Open Angle Glaucoma, Ocular Hypertension
A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.
To investigate dose response, safety and efficacy of PF-03187207 in patients with primary open-angle glaucoma or ocular hypertension
- Trial name
- NCT00595101
- Testing
- PF-03187207, Latanoprost 0.005%, PF-03187207 Vehicle
- Where
- 13 sites in Japan
- Volunteers
- 117 people
- Sponsor
- Bausch & Lomb Incorporated
Primary Open-Angle Glaucoma, Ocular Hypertension
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
The objective of this Phase 2 study is to evaluate whether the Bimatoprost Ocular Insert is non-inferior to that of timolol ophthalmic solution (0.5%) at 12 weeks.
- Trial name
- NCT01915940
- Testing
- Bimatoprost, Timolol 0.5%
- Where
- 10 sites in United States
- Volunteers
- 169 people
- Sponsor
- ForSight Vision5, Inc.
Glaucoma, Primary Open Angle, Ocular Hypertension
A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons
The study will evaluate patients diagnosed with primary open angle glaucoma or ocular hypertension who are switched to Lumigan® UD monotherapy for medical reasons in accordance with physician standard clinical practice.
- Trial name
- NCT01853085
- Testing
- Bimatoprost Ophthalmic Solution
- Where
- Germany
- Volunteers
- 1,830 people
- Sponsor
- Allergan
Primary Open Angle Glaucoma, Ocular Hypertension
Study of LL-BMT1 in Patients With Elevated Intraocular Pressure
This is an open-label, Phase 2a clinical study of LL-BMT1 in patients with primary open-angle glaucoma and ocular hypertension. Study subjects will be treated for 7 days with a single dose of LL-BMT1.
- Trial name
- NCT04747808
- Testing
- LL-BMT1
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- MediPrint Ophthalmics, Inc.
Glaucoma, Open Angle or Ocular Hypertension
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide compared with AzoptTM
- Trial name
- NCT03896633
- Testing
- brinzolamide 1% ophthalmic suspension, Azopt 1%
- Where
- United States
- Volunteers
- 637 people
- Sponsor
- Bausch & Lomb Incorporated
Primary Open-angle Glaucoma and Ocular Hypertension
Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6
This is a randomized, double-masked, parallel-group, multi-center study. Subjects diagnosed with POAG or OHT who meet eligibility criteria at Visit 1 (Screening) will wash out their current topical IOP lowering medication(s), if…
- Trial name
- NCT03858894
- Testing
- DE-117 Ophthalmic Solution QD, DE-117 Ophthalmic Solution BID
- Where
- 13 sites in United States
- Volunteers
- 98 people
- Sponsor
- Santen Inc.
Glaucoma, Open-Angle, Ocular Hypertension
Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
This study will evaluate the safety and efficacy of Triple Combination Therapy compared with Fixed Combination brimonidine tartrate/timolol ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01217606
- Testing
- bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy), Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution
- Where
- Brazil
- Volunteers
- 185 people
- Sponsor
- Allergan
Glaucoma
Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to assess the safety and efficacy of Travoprost 0.004% and Tafluprost 0.0015% in patients with primary open angle glaucoma or ocular hypertension when both medications are administered in the evening.
- Trial name
- NCT00966940
- Testing
- Travoprost 0.004% ophthalmic solution (TRAVATAN), Tafluprost 0.0015% ophthalmic solution
- Volunteers
- 51 people
- Sponsor
- Alcon Research
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
This is a study of bimatoprost as initial, replacement, or adjunctive intraocular pressure (IOP)-lowering therapy in patients with primary open angle glaucoma and ocular hypertension.
- Trial name
- LOTUS (NCT02061683)
- Testing
- Bimatoprost 0.03%
- Where
- China
- Volunteers
- 263 people
- Sponsor
- Allergan
Open Angle Glaucoma, Ocular Hypertension
DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%
DE-111 ophthalmic solution will be evaluated for superiority in comparison with Tafluprost 0.0015% ophthalmic solution, or for non-inferiority in comparison with Tafluprost 0.0015% and Timolol ophthalmic solution 0.5% used…
- Trial name
- NCT01342081
- Testing
- DE-111 ophthalmic solution, Tafluprost ophthalmic solution 0.0015%, Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%
- Where
- Japan
- Volunteers
- 489 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.